GlassScriptPhysician profile
Haley B Pemberton
NPI 1770268138
$3,886.80
in general payments reported to CMS, 2019-2025
31 companies · $2,209 in 2025
The $2,209 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $301 · 2024: $1,377 · 2025: $2,209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,887.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,886.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $554.35 | 2023-2025 | Ingrezza |
| Novo Nordisk INC | $478.93 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $461.83 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $300.10 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $193.76 | 2023-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.30 | 2023-2025 | Ofev, Jascayd |
| Ardelyx, INC. | $167.11 | 2024-2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $133.25 | 2023-2025 | |
| Glaxosmithkline, LLC. | $129.09 | 2024-2025 | Trelegy Ellipta |
| Abbvie INC. | $126.59 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.03 | 2023-2025 | Xifaxan |
| Sumitomo Pharma America, INC. | $97.59 | 2023-2025 | Gemtesa |
| Lundbeck LLC | $90.25 | 2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $84.91 | 2023-2024 | Trintellix |
| Astellas Pharma US INC | $79.57 | 2023-2025 | Veozah |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $79.48 | 2024-2025 | Mounjaro, Zepbound |
| Axsome Therapeutics, INC. | $77.25 | 2025 | Auvelity |
| Ucb, INC. | $67.82 | 2024 | Nayzilam, Briviact |
| Teva Pharmaceuticals USA, INC. | $58.91 | 2025 | Austedo Xr |
| Exact Sciences Corporation | $54.10 | 2024-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $51.03 | 2024 | Voquezna |
| Amgen INC. | $48.66 | 2024-2025 | Repatha, Otezla, Repatha |
| Corium, LLC | $46.04 | 2023-2024 | Azstarys |
| Intuitive Surgical, INC. | $44.92 | 2025 | |
| Mylan Specialty L.P. | $38.52 | 2024 | Yupelri |
| Ironwood Pharmaceuticals, INC | $36.52 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.00 | 2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $24.00 | 2025 | Qelbree |
| Janssen Pharmaceuticals, INC | $23.32 | 2024 | Xarelto |
| Abbott Laboratories | $19.67 | 2025 | Freestyle Libre 3 |
| Shield Therapeutics INC | $18.90 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haley Pemberton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.